Literature DB >> 16586562

Sporadic somatic mutation of c-kit gene in a family with gastrointestinal stromal tumors without cutaneous hyperpigmentation.

Chun-Nan Yeh1, Tsung-Wen Chen, Yi-Yin Jan.   

Abstract

We described two members in a family with gastrointestinal stromal tumors (GISTs) without cutaneous hyperpigmentation. The patients were father and son who did not have cutaneous hyperpigmentation. Histological examination showed that these tumors were GISTs expressing CD34 and CD117. Tumor DNA extracted from paraffin-embedded specimens revealed somatic mutation with a deletion mutation at different codons in exon 11 of c-kit gene after direct sequencing analysis. No germline mutation was detected in DNA extracted from peripheral leukocytes obtained from the father and son. We propose that GISTs could be caused by sporadic somatic mutation in a family without germline mutation and hyperpigmentation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16586562      PMCID: PMC4124368          DOI: 10.3748/wjg.v12.i11.1813

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  9 in total

1.  The management of retroperitoneal soft tissue sarcoma.

Authors:  J J Lewis; M F Brennan
Journal:  Adv Surg       Date:  1999

2.  Familial gastrointestinal stromal tumours with germline mutation of the KIT gene.

Authors:  T Nishida; S Hirota; M Taniguchi; K Hashimoto; K Isozaki; H Nakamura; Y Kanakura; T Tanaka; A Takabayashi; H Matsuda; Y Kitamura
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

3.  Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene.

Authors:  H Maeyama; E Hidaka; H Ota; S Minami; M Kajiyama; A Kuraishi; H Mori; Y Matsuda; S Wada; H Sodeyama; S Nakata; N Kawamura; S Hata; M Watanabe; Y Iijima; T Katsuyama
Journal:  Gastroenterology       Date:  2001-01       Impact factor: 22.682

4.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

5.  Gastrointestinal sarcomas. Analysis of prognostic factors.

Authors:  P C McGrath; J P Neifeld; W Lawrence; S Kay; J S Horsley; G A Parker
Journal:  Ann Surg       Date:  1987-12       Impact factor: 12.969

6.  Leiomyosarcoma of the small and large bowel.

Authors:  O E Akwari; R R Dozois; L H Weiland; O H Beahrs
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

7.  Myosarcomas of the stomach: natural history, prognostic factors and management.

Authors:  M H Shiu; G H Farr; D N Papachristou; S I Hajdu
Journal:  Cancer       Date:  1982-01-01       Impact factor: 6.860

8.  PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor.

Authors:  Agnès Chompret; Caroline Kannengiesser; Michel Barrois; Philippe Terrier; Philippe Dahan; Thomas Tursz; Gilbert M Lenoir; Brigitte Bressac-De Paillerets
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682

9.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura S McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

  9 in total
  1 in total

Review 1.  Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.

Authors:  S Farag; L E van der Kolk; H H van Boven; A C J van Akkooi; G L Beets; J W Wilmink; N Steeghs
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.